Neutropenia biologic drug treatment refers to drugs that are used to reduce fevers or potential infections as well as activate the bone marrow and boost neutrophil production. A lack of neutrophils, a particular type of white blood cell, causes neutropenia. The main types of drugs in neutropenia biologic drug treatment are filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim is a recombinant form of granulocyte colony-stimulating protein that is given as an injection to boost neutrophil production after chemotherapy. The different types of treatments include antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, and others, and are distributed through various channels such as retail pharmacies, hospital pharmacies, and online pharmacies. The neutropenia biologic drug treatment market research report is one of a series of new reports from The Business Research Company that provides neutropenia biologic drug treatment market statistics, including global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global neutropenia biologic drug treatment market grew from $11.26 billion in 2022 to $12.29 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neutropenia biologic drug treatment market is expected to grow from $15.79 billion in 2027 at a CAGR of 6.5%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the market for neutropenia biologic drugs. Due to a growing cancer incidence and an increase in the number of people opting for chemotherapy, there has been an increase in the number of people suffering from neutropenia. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the neutropenia biologic drug treatment market over the forthcoming years. The introduction of biosimilars as a result of patent expiry is expected to hamper the growth of the neutropenia biologic drug treatment market. Biosimilar is a therapeutic agent that has high similarity with the original biological product in action but is available at a lower cost than the original product. Biosimilars are mostly priced at 70% of the price of branded drugs and are likely to replace expensive branded drugs. For instance, in May 2022, Biocon Biologics Limited, an India-based biopharmaceutical company specialising in the development of biological drugs, launched Abevmy® (bBevacizumab) in collaboration with Viatris Inc., a US-based healthcare and biopharmaceutical company pioneering in the development of medicines, advancing sustainable operations, and developing innovative solutions. Abevmy® (bBevacizumab) is being developed to treat various types of cancer, including solid tumors. Companies in the neutropenia biologic drug treatment market are increasingly investing in developing novel drug delivery systems to improve the therapeutic response of the drug and increase its efficacy. Novel drug delivery systems allow the delivery of a very high dose of drugs directly into the neutrophils, while the systemic dose remains low, thus disabling side effects. For instance, in August 2020, Asalyxa Bio announced its formation and seed funding to accelerate ASX-100 into first-in-human trials in 2021. ASX-100 is a novel spherical particle that releases a safe and effective anti-inflammatory agent, salicylic acid, directly to over-reactive immune cells and is used for treating severe neutrophil-mediated disease. In September 2020, Gilead Sciences, a US-based biopharmaceutical company, launched Immunomedics for $21 billion. Through this acquisition, Gilead will get TrodelvyTM ( acituzumabgovitecan-hziy), which will alter Gilead’s portfolio by adding a first-in-class commercial drug with considerable revenue potential and best-in-class potential. Immunomedics is a biotechnology company based in the United States that provides biologic drug treatment for neutropenia. Major players in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp., Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics. North America was the largest region in the neutropenia biologic drug treatment market in 2022. The regions covered in the global neutropenia biologic drug treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global neutropenia biologic drug treatment market is segmented - 1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim 2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types 3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

G-CSF (granulocyte colony stimulating factors) refers to a type of colony-stimulating factor that aids in the bone marrow's ability to produce more white blood cells. Patients who have specific tumours, neutropenia brought on by some types of chemotherapy, or severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it. The main types of G-CSF are lenograstim (granocyte), filgrastim (neupogen, zarzio, nivestim, accofil), long acting (pegylated) filgrastim (pegfilgrastim, neulasta, pelmeg, ziextenco), and lipegfilgrastim (lonquex). Lenograstim is a glycosylated recombinant therapeutic drug that is chemically similar to or identical to a naturally occurring human granulocyte colony-stimulating factor (G-CSF). The different products include tablets, capsules, and others and are used in oncological diseases, blood disorders, growth hormone deficiencies, and chronic and autoimmune disorders, among others. The G-CSF (Granulocyte Colony Stimulating Factors) market research report is one of a series of new reports from The Business Research Company that provides G-CSF (Granulocyte Colony Stimulating Factors) market statistics, including G-CSF (Granulocyte Colony Stimulating Factors) industry global market sizes, regional shares, competitors with a G-CSF (Granulocyte Colony Stimulating Factors) market share, detailed G-CSF (Granulocyte Colony Stimulating Factors) market segments, market trends and opportunities, and any further data you may need to thrive in the G-CSF (Granulocyte Colony Stimulating Factors) industry. This G-CSF (granulocyte colony stimulating factors) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global g-csf (granulocyte colony stimulating factors) market grew from $7.99 billion in 2022 to $8.43 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The g-csf (granulocyte colony stimulating factors) market is expected to grow from $9.94 billion in 2027 at a CAGR of 4.2%. The increasing prevalence of cancer is a key factor driving the growth of the G-CSF (granulocyte colony stimulating factor) market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. For instance, in December 2020, according to the International Agency for Research on Cancer (IARC), a France-based intergovernmental agency that publishes research and data on cancer, it is anticipated that 28.4 million new cases of cancer will be diagnosed worldwide in 2040, up 47% over the anticipated 19.3 million cases in 2020, primarily due to population growth and aging. G-CSF is a class of growth factors that produce white blood cells in the bone marrow to minimise the risk of infection and sepsis. In cancer patients, G-CSF accelerates recovery and reduces mortality from neutropenia after chemotherapy for cancer. It can also reduce infections after certain forms of cancer treatment. Therefore, the increasing prevalence of cancer is expected to drive the growth of the G-CSF market. The high cost is a key factor limiting the growth of the G-CSF market. Improved chemotherapy administration is responsible for the rise in immediate medical expenses in breast cancer patients receiving primary prophylactic (PP) G-CSF. According to a study conducted by the American Journal of Managed Care, PPG-CSF administration in the first chemotherapy class was associated with a 57% increase in total Medicare costs during the study period, despite a fall in medical costs for neutropenia. Around 42% of the increase can be attributed to the rise in the cost of chemotherapy. Each shot of PPG-CSF costs more than $250. Therefore, the high cost is expected to hinder the growth of the G-CSF (granulocyte colony stimulating factor) market. Companies in the G-CSF market are focusing on strategic collaborations for developing innovative products and increasing market share. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out-licensing deals, has been increasing over recent years. For example, in 2022, Evive Biotech, a Singapore based biopharmaceutical company collaborated with Germany based pharmaceutical company, APOGEPHA to enter into an exclusive long-term license agreement for the commercialization of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627 is a novel dimeric G-CSF long-acting fusion protein without pegylation. In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specialising in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, G-CSF drugs would be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of biosimilars for the treatment of eye related diseases. Major players in the G-CSF (granulocyte colony stimulating factors) market are BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, StadaArzneimittel, Dong-A Socio Group, Amgen, Dr. Reddy's Laboratories, and Celltrion Inc. North America was the largest region in the G-CSF granulocyte colony stimulating factors market in 2022. The regions covered in the global G-CSF (granulocyte colony stimulating factor) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the G-CSF (granulocyte colony stimulating factor) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The G-CSF (granulocyte colony stimulating factors) market consists of sales of releuko, accofil, and pegylated. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global G-CSF (granulocyte colony stimulating factors) market is segmented - 1) By Type: Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Accofil), Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco), Lipegfilgrastim (Lonquex) 2) By Application: Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic And Autoimmune Disorders, Other Applications 3) By Product: Tablet, Capsule, Other Products

Pegfilgrastim biosimilars refer to a biosimilar that is intended to be used in conjunction with supportive care for people with non-myeloid cancer. It can help prevent or treat infections brought on by myelosuppressive chemotherapy by promoting the formation of certain white blood cells. The different applications of pegfilgrastim biosimilars are chemotherapy treatment, transplantation, and others. Chemotherapy is a cancer treatment that involves the administration of one or more anti-cancer medications as part of a defined protocol. The various distribution channels include hospital pharmacies, retail pharmacies, and mail-order pharmacies. The pegfilgrastim biosimilars market research report is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market statistics, including pegfilgrastim biosimilars industry global market size, regional shares, competitors with a pegfilgrastim biosimilars market share, detailed pegfilgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. This pegfilgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pegfilgrastim biosimilars market grew from $1.28 billion in 2022 to $1.41 billion in 2023 at a compound annual growth rate (CAGR) of 10.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pegfilgrastim biosimilars market is expected to grow from $2.04 billion in 2027 at a CAGR of 9.7%. Government initiatives for the development of biosimilars are expected to drive the pegfilgrastim biosimilars market. Governments worldwide are focusing on the development of biosimilars due to their cost-effective nature. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan, to increase treatment options. The Australian government is committed to the Biosimilar Awareness Initiative, and they improved their commitment by supporting the Generic and Biosimilar Medicines Association through a grant of $5 million to accept increased general biosimilar education and activities that promote the suitable dispensing, prescription, and use of biosimilar medicines. Hence, the government initiatives for the development of biosimilars aid in the increased production and awareness that, in turn, support the growth of the pegfilgrastim biosimilars market. The FDA's low number of drug approvals hampered the pegfilgrastim biosimilar market during the forecast period.The market currently has only four drugs approved for treatment, thus restricting the growth of the market. This can be attributed to strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market. Companies in the pegfilgrastim biosimilar market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships or out-licensing deals, this trend has been increasing over the past few years. For instance, in April 2020, Biocon, an India-based biopharmaceutical company, partnered with Mylan, a US-based generic and specialty pharmaceuticals company, to introduce Fulphila, a biosimilar pegfilgrastim, in Australia. Fulphila has been licenced by the Therapeutic Goods Administration for the therapy of oncology patients who have had chemotherapy to shorten the length of acute neutropenia and hence the risk of infection, as evidenced by febrile neutropenia. In February 2022, Biocon Biologics Ltd., an India-based fully integrated biopharmaceutical company, acquired Viatris ' biosimilar business for $3.34 billion. Through this acquisition, BBL would be able to direct-market more of its existing and upcoming biosimilars. In order to maintain customer service and facilitate a smooth transition to BBL, Viatris is expected to provide commercial and other transition services with this acquisition for an anticipated two-year term. Viatris Inc is a US-based pharmaceutical and healthcare corporation that has co-developed a biosimilar of pegfilgrastim. Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals, and Fresenius Kabi. North America was the largest region in the pegfilgrastim biosimilars market in 2022. The Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market during the forecast period. The regions covered in the global pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global pegfilgrastim biosimilars market is segmented - 1) By Application: Chemotherapy Treatment, Transplantation, Other Applications 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs. The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others. The biosimilars market research report is one of a series of new reports from The Business Research Company that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilars market grew from $19.1 billion in 2022 to $23.28 billion in 2023 at a compound annual growth rate (CAGR) of 21.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilars market is expected to grow from $47.82 billion in 2027 at a CAGR of 19.7%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market. The lack of awareness about biosimilars among primary care physicians (PCPs) and specialists limits the growth of the biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of familiarity with biosimilars reduces the likelihood of prescribing the drugs to patients which affects the demand for new biosimilars in the market. For instance, according to the PwC’s Health Research Institute, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the biosimilars market. Production of new insulin biosimilars is trending in the biosimilars market. The key players operating in the biosimilars market are investing in creating a biosimilar of insulin. This is also promoting competition among various biosimilar manufacturers. For instance, in August 2020, Biocon Biologics India Ltd., an India-based fully integrated global biosimilars organization, in partnership with Mylan, a US-based biosimilar company, has launched Semglee, insulin glargine injection in the U.S. to aid in lowering blood sugar levels in adults with type 2 diabetes and children with type 1 diabetes. Major players in the biosimilars market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, STADA Arzneimittel, Sandoz International, Samsung Bioepis, Teva Pharmaceuticals, Apotex, AMEGA Biotech S.A., Bioton S.A., Innovent Biologics International, Allergan PLC., BioXpress Therapeutics, 3SBio, Intas Biopharmaceuticals, Lupin Merck, Novartis, Ratiopharm, Wockhardt, Zydus Cadila, Allergan PLC., Hospira International., Actavis International., Johnson & Johnson and Roche. North America was the largest region in the global biosimilars market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilars market is segmented - 1) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins 2) By Types: Human Growth Hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Other Types 3) By Application: Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biologic cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy. The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies. The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global oncology biosimilars market grew from $4.19 billion in 2022 to $5.38 billion in 2023 at a compound annual growth rate (CAGR) of 28.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oncology biosimilars market is expected to grow from $12.83 billion in 2027 at a CAGR of 24.3%. The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars. The lack of awareness of biosimilars among primary care physicians (PCPs) and specialists limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of detailed awareness of the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market. The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus plan to build a leading immuno-oncology franchise using cash from its commercial biosimilar business. Also, in 2019, Biocon, India’s largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up an R&D facility to boost biosimilar development. Major players in the oncology biosimilars market are Bitcoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan, and F Hoffmann-La Roche. North America was the largest region in the global oncology biosimilars market in 2022. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the global oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global oncology biosimilars market is segmented - 1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF) 2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types 3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Trastuzumab biosimilar refers to a HER2-targeted therapy drug that is designed to treat early and metastatic HER2-positive breast cancers. Trastuzumab biosimilar is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2)/neu receptor and renders it inactive The main types of products in trastuzumab biosimilars are ogivri, herzuma, ontruzant, trazimera, and others. The different indications include adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, and others, and they are distributed through hospital pharmacies and online pharmacies. The trastuzumab biosimilar market research report is one of a series of new reports from The Business Research Company that provides trastuzumab biosimilar market statistics, including trastuzumab biosimilar industry global market size, regional shares, competitors with a trastuzumab biosimilar market share, detailed trastuzumab biosimilar market segments, market trends and opportunities, and any further data you may need to thrive in the trastuzumab biosimilar industry. This trastuzumab biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global trastuzumab biosimilars market grew from $2.64 billion in 2022 to $3.36 billion in 2023 at a compound annual growth rate (CAGR) of 27.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The trastuzumab biosimilars market is expected to grow from $8.86 billion in 2027 at a CAGR of 27.4%. The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilar market. Trastuzumab biosimilar is used in the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. According to the World Health Organization (WHO), breast cancer affected 2.3 million women globally in 2020, with 685 000 fatalities. According to Cancer India, breast cancer is the most common cancer in women in India and accounts for 14% of the cancers in women. Therefore, the rising prevalence of breast and gastric cancer increases the demand for trastuzumab biosimilar that helps save money when compared to expensive medicines, thereby driving the market. The side effects of trastuzumab biosimilar are expected to limit the growth of the trastuzumab biosimilar market. The side effects of Herceptin (chemical name: Trastuzumab) include diarrhea, nausea, fever, heart problems, infection, cough, and rashes. Moreover, breast cancer studies reflect that exposure to trastuzumab (Herceptin) therapy increased the rate of asymptomatic cardiac dysfunction in the two-year trastuzumab treatment from 4.6% to 8.1%. The rate of at least one patient experiencing Grade-3 or higher, for treatment with trastuzumab is at 20.4% for two years, compared to 16.1% for one year of treatment. The side effects of trastuzumab hurt the trastuzumab biosimilar market. Major players are continuously focusing on launching new products in the untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the trastuzumab biosimilars market are undergoing various strategic initiatives such as new product development, partnerships, and geographical and product portfolio expansion to maintain their competitive position in the market and better serve the needs of the customers. For instance, in February 2020, Pfizer launched trastuzumab biosimilar to Herceptin, Trazimera in the USA. Trazimera is available for the treatment of human epidermal growth factor receptor 2 (HER2) metastatic gastric and breast cancer. Furthermore, in April 2020, Merck announced the launch of a Biosimilar of Herceptin (trastuzumab)- ONTRUZANT(trastuzumab-dttb). ONTRUZANT is available in the USA for approximately $1,325 and $3,709 for the 150 mg single-dose and 420 mg multiple-dose vial, respectively. In March 2022, Biocon Biologics, an India-based fully integrated biopharmaceutical company, acquired Viatris Inc for $3.3 billion. This acquisition would build a distinctive, fully integrated, global biosimilars enterprise. This strategic alliance combines the strengths and complementary skills of both parties, positioning Biocon Biologics for the next ten years of value generation for all of our stakeholders. Viatris Inc is a US-based pharmaceutical company and a developer of biosimilar trastuzumab. Major players in the trastuzumab biosimilar market are Amgen Inc., Pfizer Inc., Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd. and EirGenix, Inc. North America was the largest region in the trastuzumab biosimilar market in 2022. Middle East is expected to be the fastest growing region in the global trastuzumab biosimilars market during the forecast period. The regions covered in the global trastuzumab biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the trastuzumab biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The trastuzumab biosimilar market consists of sales of herceptin, avastin, and Kanjinti. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global trastuzumab biosimilars market is segmented - 1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products 2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

Rituximab biosimilar refers to a chimeric monoclonal antibody that is directed against the immune system's B cell-specific protein CD20. Rituximab kills B cells, making it useful for treating conditions where there are too many, too active, or otherwise abnormal B cells. The main routes of administration for rituximab biosimilars are subcutaneous, intravenous, and molecular. Intravenous therapy is a medical procedure in which fluids, drugs, and nutrients are delivered straight into a patient's vein. The different applications include non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others, and are distributed through various channels such as hospital pharmacies, online pharmacies, retail pharmacies, and other direct distribution channels. The rituximab biosimilars market research report is one of a series of new reports from The Business Research Company that provides rituximab biosimilars market statistics, including rituximab biosimilars industry global market sizes, regional shares, competitors with a rituximab biosimilars market share, detailed rituximab biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the rituximab biosimilars industry. This rituximab biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global rituximab biosimilars market grew from $2.05 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 14.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The rituximab biosimilars market is expected to grow from $3.84 billion in 2027 at a CAGR of 13.1%. The rising prevalence of non-Hodgkin's lymphoma (NHL) is predicted to contribute to the growth of the rituximab biosimilars market. Non-Hodgkin's lymphoma, or lymphoma, is cancer that starts in white blood cells, and lymphocytes that are part of the body’s immune system. According to the American Cancer Society, NHL is the most common cancer in the USA, accounting for about 4% of all cancers. In the United States, approximately 81,560 people (45,630 men and 35,930 women) will be diagnosed with NHL in 2021.Thus, growing cases of non-Hodgkin's lymphoma are predicted to generate high demand for rituximab biosimilars over the forecast period. The high cost associated with rituximab biosimilars acts as a major restraint for the growth of rituximab’s market over the upcoming years. The cost of the subcutaneous option was costlier than IV biosimilar rituximab. Subcutaneous formulation costs between $3,805 and $8,807 for patients with small bodies, and between $325 and $6109 and $484 and $6267 for patients with medium bodies for two infusion speeds.The high costs of rituximab biosimilars make it unaffordable for the treatment of patients with low income, hindering the growth of the market. The companies operating in the biosimilars industry are continuously focusing on new product development in collaboration with other companies operating in the industry. Innovations through partnerships are shaping the market for rituximab biosimilars. For instance, in May 2020, Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare Co. Ltd. jointly announced the launch of biosimilar Truxima (rituximab-abbs) injection in the USA for the treatment of polyangiitis and rheumatoid arthritis. Truxima is the only biosimilar to Roche's Rituxan (rituximab) available in the USA for the treatment of rheumatoid arthritis. Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., and Celltrion Healthcare Co. Ltd., Sandoz International GmbH, Reliance Life Sciences, C.H. Boehringer Sohn AG & Co. KG, BioXpress Therapeutics SA, and Intas Biopharmaceuticals Ltd. North America was the largest region in the rituximab biosimilars market in 2022. The Middle East is expected to be the fastest-growing region in the global rituximab biosimilars market during the forecast period. The regions covered in the global rituximab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the rituximab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The rituximab biosimilar market consists of sales of mabthera, truxima, ruxience, or rixathon. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global rituximab biosimilars market is segmented - 1) By Application: Non-Hodgkin's Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis, Other Applications 2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels 3) By Route Of Administration: Subcutaneous, Intravenous, Molecular Type

Oral Biologics & Biosimilars Market Definition

The oral biologics and biosimilars market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, and cancer. Biologics are drugs made from living cells using highly complex technology, while biosimilars are biological products which are being produced to be identical to a biologic already approved, known as reference drugs. Biosimilars should have similar safety and efficacy compared to the reference biologic product. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs through oral delivery route, for the treatment of chronic diseases.